New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer 10h
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FR?-targeting ADC at ESMO 2026 24 October
Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020 22 October
